Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Reuters
Reuters
Business

Teva's asthma treatment fails late-stage studies

(Reuters) - Teva Pharmaceutical Industries said on Monday two late-stage studies testing its treatment for asthma did not meet their main goals.

The studies were testing Teva's subcutaneous dosing of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils.

The drug is already approved as an intravenous shot to treat patients with severe asthma.

(Reporting by Manas Mishra in Bengaluru; Editing by Martina D'Couto)

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.